What you are comparing
PRP is prepared from a peripheral-blood draw. Platelets and plasma proteins are concentrated and injected. It is autologous in the usual clinic sense. It is not a stem-cell therapy, even when the website groups it under regenerative medicine. AAOS OrthoInfo discusses PRP as a musculoskeletal adjunct with still-developing evidence.
Products sold as stem-cell therapy are a mixed bag: bone-marrow concentrate, fat-derived stromal vascular fraction, birth-tissue or umbilical products, cultured cells, or exosome vials. FDA consumer alerts treat many of these as unapproved drugs when they are marketed to treat diseases. They are not one technology and they are not interchangeable with PRP.
The comparison that helps you shop is identity, regulation, evidence for your diagnosis, harvest burden, and cost. “More regenerative” is not a medical category. NIAMS osteoarthritis materials still emphasize exercise, weight, medicines, and, when needed, surgery—not a vial that claims to grow a new joint.
This guide is for adults offered both at an orthopedic or longevity clinic. It is not about FDA-approved hematopoietic transplants for blood cancers or other licensed cellular products listed on FDA’s approved-products page. Those live in hospitals and trials, not in a cash anti-aging menu.
How they differ
Source and processing differ. PRP uses blood and a centrifuge or kit. Stem-cell marketing may add marrow harvest, liposuction, donor tissue, culture, or shipping from a third-party processor. Each step adds infection, contamination, and identity questions. FDA has warned about poor manufacturing and illegal marketing.
Evidence differs. PRP has randomized trials and reviews in selected tendons and knee osteoarthritis, with heterogeneous preparations. Clinic stem-cell packages often cite basic science or uncontrolled case series while advertising many unrelated diseases. That mismatch is a red flag, not a research update.
Regulation differs. An FDA-cleared blood-processing device does not approve PRP for every claim a clinic prints. For cells and tissues marketed to treat disease, FDA generally expects approval or a lawful investigational trial. FDA’s patient pages state that unapproved products have been linked to serious harm, including infections, blindness, and tumors.
Cost and recovery differ. PRP is usually a same-day blood draw and injection. Marrow or fat harvest is more invasive and more expensive. Donor-tissue vials can be cheaper to the clinic and still costly to you. Higher price does not mean higher-quality cells or better outcomes.
- PRP: platelets from your blood; not stem cells; mixed MSK evidence.
- Marketed stem cells: many sources; often unapproved for the advertised use.
- Approved cellular products: specific indications, not longevity menus.
Who each option is for
PRP may be considered for a person with a defined tendon or knee-osteoarthritis problem who understands the mixed evidence, will do rehabilitation, and has a licensed musculoskeletal clinician. It is not for someone seeking a youth reset or a substitute for indicated joint replacement counseling.
Legitimate cellular therapy may be appropriate only for a labeled indication or a registered trial with informed consent, eligibility criteria, and safety monitoring. That is a narrow door. It is not a walk-in clinic that treats Parkinson disease, COPD, and wrinkles with the same amniotic product.
People with active infection, cancer in the field, or a need for urgent structural repair are not candidates for shopping either product as first-line care. Immunosuppressed patients should be especially cautious about unstandardized injectables.
If you cannot get a plain-language product name, lot, and regulatory basis, you are not an informed candidate. FDA tells consumers to be skeptical of products from adipose tissue, Wharton’s jelly, amniotic fluid, and exosomes sold for broad cures.
Risks of choosing the wrong one
The core risk of treating PRP as stem-cell therapy is false expectation. You may pay stem-cell prices for a blood product, or you may skip a better-studied PRP protocol because the clinic upsold an unapproved vial. Mislabeling also confuses later clinicians who need to know what entered the joint.
The core risk of unapproved stem-cell clinics is harm plus delay. FDA has documented serious infections and other injuries. Time spent on a miracle injection can postpone physical therapy, rheumatology, or surgery that would have protected function. Blindness after periocular injections is not a theoretical talking point.
Financial harm is real. Packages can cost thousands without a refund when function is unchanged. Travel add-ons and “booster” visits multiply the bill. A clinic that requires prepayment for a series before a diagnosis is confirmed is selling a course, not practicing stepwise care.
Legal and trial confusion is another risk. Being told a product is “FDA-approved because the device is cleared” or “legal because it is your own cells” is a common dodge. Your own cells can still be a regulated drug after more-than-minimal manipulation or when marketed for a new disease claim.
How to decide
Name the diagnosis first with a licensed clinician. If the problem is a tendon or osteoarthritic knee, ask whether PRP evidence applies and what rehabilitation sits beside it. If the pitch is stem cells for aging, arthritis, and neurologic disease together, stop.
Ask for the product insert, tissue source, processing site, and either an approval or an IND trial number you can look up. Compare that with FDA’s approved cellular-product list. If staff become hostile when you ask, that is data.
Compare harms and costs in writing. Include harvest anesthesia, time off work, infection precautions, and who manages complications. Prefer clinicians who also offer noninjection care and will say no.
Keep records of what was injected. Do not treat either option as anti-aging. PRP is a blood product with limited, condition-specific evidence. Stem-cell clinic marketing is often unapproved. The safer decision is the one that stays inside licensed musculoskeletal care and FDA’s public warnings.
Frequently Asked Questions
References
FDA: Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes
https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomesFDA: Important Patient and Consumer Information About Regenerative Medicine Therapies
https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapiesAAOS OrthoInfo: Platelet-Rich Plasma (PRP)
https://orthoinfo.aaos.org/en/treatment/platelet-rich-plasma-prp/NIAMS: Osteoarthritis
https://www.niams.nih.gov/health-topics/osteoarthritisFDA: Approved Cellular and Gene Therapy Products
https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
Your Privacy Choices